Skip to main content
SpringerLink
Log in

Ribociclib: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ribociclib is an oral, small-molecule inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis for the treatment of cancer. CDKs play an important role in cell cycle progression and cellular proliferation, and inhibition of these kinases with ribociclib results in G1 phase cell-cycle arrest. Ribociclib, in combination with an aromatase inhibitor, was recently approved in the USA for the first-line treatment of advanced breast cancer and has been submitted for approval in the EU for this indication. Ribociclib is undergoing further phase III investigations in breast cancer and is being evaluated in phase I or II trials for various solid tumour types and haematological malignancies. This article summarizes the milestones in the development of ribociclib leading to this first global approval for use as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Novartis Pharmaceuticals. KISQALI® (ribociclib) tablets, for oral use: US prescribing Information. 2017. https://www.fda.gov. Accessed 31 Mar 2017.

  2. Caldon CE, Daly RJ, Sutherland RL, et al. Cell cycle control in breast cancer cells. J Cell Biochem. 2006;97(2):261–74.

    Article  CAS  PubMed  Google Scholar 

  3. Network Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

    Article  Google Scholar 

  4. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013;10(4):191–210.

    Article  CAS  PubMed  Google Scholar 

  5. Novartis. Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2− advanced breast cancer [media release]. 03 Aug 2016. http://www.novartis.com.

  6. Novartis. Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2− advanced breast cancer [media release]. 02 Nov 2016. http://www.novartis.com.

  7. Astex Pharmaceuticals. Astex achieves milestone on US FDA filing of New Drug Application (NDA) for LEE011 (ribociclib) plus letrozole as a first-line treatment for HR+/HER2− advanced breast cancer [media release]. 3 Nov 2016. http://www.astx.com.

  8. Astex Therapeutics. Astex announces new licensing and drug discovery alliance to develop novel cell cycle cancer drugs [media release]. 6 Dec 2005. http://www.astex-therapeutics.com.

  9. Astex Therapeutics. Astex announces milestone in oncology collaboration [media release]. 11 Jan 2011. http://www.asthex.therapeutics.com.

  10. Kim S, Loo A, Chopra R, et al. Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6–reactivating Rb in cancer [abstract no. PR02]. Mol Cancer Ther. 2013;12(11 Suppl).

  11. Radius. Radius Health announces clinical collaboration with a leading pharmaceutical company to evaluate RAD1901 combination regimens in advanced breast cancer [media release]. 27 Jan 2016. http://www.radiuspharm.com.

  12. Chen P, Lee NV, Hu W, et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther. 2016;15(10):2273–81.

    Article  CAS  PubMed  Google Scholar 

  13. O’Brien NA, Tomaso ED, Ayala R, et al. In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res. 2014;74(19 Suppl 1).

  14. Tao YF, Wang NN, Xu LX, et al. Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells. Cancer Cell Int. 2017;17(35):1–17.

    Google Scholar 

  15. Bortolozzi R, Mattiuzzo E, Mariotto E, et al. CDK4/CDK6 inhibition in childhood B-acute lymphoblastic leukemia: a new strategy to mediate glucocorticoid sensitivity [abstract no. 1297]. Cancer Res. 2016;76(14 Suppl).

  16. Infante JR, Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016;22(23):5696–705.

    Article  CAS  PubMed  Google Scholar 

  17. Curigliano G, Gomez Pardo P, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191–8.

    Article  CAS  PubMed  Google Scholar 

  18. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.

    Article  CAS  PubMed  Google Scholar 

  19. Juric D, Minister PN, Campone M, et al. Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced breast cancer (aBC): phase Ib safety, preliminary efficacy and molecular analysis [abstract no. 568 plus poster]. J Clin Oncol. 2016;34(Suppl.).

  20. Munster P, Ismail-Khan R, Garcia-Estevez L, et al. Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2− advanced breast cancer [abstract no. P4-22-18 plus poster]. Cancer Res. 2017;77(4 Suppl.).

  21. Juric D, Ismail-Khan R, Campone M, et al. Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2-breast cancer: safety, preliminary efficacy and molecular analysis [abstract no. P3-14-01]. Cancer Res. 2016;76(4 Suppl.).

  22. Tolaney SM, Forero-Torres A, Boni V, et al. Ribociclib + fulvestrant in postmenopausal women with HR+, HER2− advanced breast cancer (ABC) [abstract no. P4-22-12]. Cancer Res. 2016;77(4 Suppl).

  23. Bardia A, Modi S, Oliveira M, et al. Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2− advanced breast cancer [abstract no. P6-13-01 plus poster]. Cancer Res. 2016;76(4 Suppl.).

  24. Peguero JA, O’Neil BH, Sohal D, et al. Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the SIGNATURE program [abstract no. 2528]. J Clin Oncol. 2016;34(Suppl).

  25. Seront E, Schmitz S, Rottey S, et al. Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck [abstract no. 1002P]. Ann Oncol. 2016;27(Suppl 6).

  26. Van Herpen C, Postow MA, Carlino MS, et al. A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma [abstract no. 3300 plus slides]. Eur J Cancer. 2015;51(Suppl 3):S663.

    Article  Google Scholar 

  27. Taylor M, Sosman J, Gonzalez R, et al. Phase Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF-mutant melanoma [abstract no. 1086O]. Ann Oncol. 2014;25(Suppl. 4):iv374–5.

  28. Geoerger B, Bourdeaut F, Dubois SG, et al. Phase I study of LEE011 (CDK4/6 inhibitor) in patients with malignant rhabdoid tumors, neuroblastoma, and cyclin D-CDK4/6 pathway-activated tumors [abstract no. 455 plus poster]. Ann Oncol. 2014;25(Suppl. 4).

  29. Fasching PA, Decker T, Fehm T, et al. RIBECCA—a phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole [abstract no. OT2-01-18 plus poster]. Cancer Res. 2017;77(4 Suppl.).

  30. Khan QJ, Prochaska LH, Yuan Y, et al. Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer—the FELINE trial [abstract no. OT3-02-06 plus poster]. Cancer Res. 2017;77(4 Suppl.).

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Yahiya Y. Syed

Authors
  1. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yahiya Y. Syed.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. Ribociclib: First Global Approval. Drugs 77, 799–807 (2017). https://doi.org/10.1007/s40265-017-0742-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0742-0

Keywords

Search

Navigation